Several clinical trial studies have been initiated for this combined MEK/ERK and autophagy inhibition in RAS-mutant cancers including PDAC (NCT03825289, NCT04132505, NCT04214418, NCT04386057, and NCT04145297; https://clinicaltrials.gov). The gene discussed is MAP2K7; the disease is cancer.